Literature DB >> 15232173

Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection.

Michael Batzloff1, Huaru Yan, Mark Davies, Jon Hartas, Michael Good.   

Abstract

BACKGROUND &
OBJECTIVES: Infection with group A Streptococcus (GAS) may result in a number of human diseases ranging from the relatively benign pharyngitis to the potentially life-threatening invasive diseases and post-infectious sequelae. We have previously defined a minimal B-cell epitope from the conserved region of the M-protein. Here we report on the immunogenicity, opsonic potential of the resulting sera and the level of protection induced by this peptide in comparison to a pepsin extract of the M protein.
METHODS: Inbred mice were immunized with peptides derived from the M protein. Sera were collected from the immunized mice and its opsonic potential determined for M1 and M6 GAS strains. Mice were then intranasally challenged with a virulent M1 GAS strain to determine the protective efficacy of the peptides.
RESULTS: The peptides induced significant antibody responses when delivered subcutaneously and immunized mice demonstrated significantly enhanced survival compared to control groups following challenge. INTERPRETATION &
CONCLUSION: The data obtained in the present study indicated that the chimeric peptide J8 from the conserved region of the M protein could form the basis for an anti-streptococcal vaccine in future.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15232173

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  6 in total

Review 1.  Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.

Authors:  Michael R Batzloff; Manisha Pandey; Colleen Olive; Michael F Good
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 2.  Prevention and treatment of rheumatic heart disease in the developing world.

Authors:  Andrew C Steer; Jonathan R Carapetis
Journal:  Nat Rev Cardiol       Date:  2009-09-15       Impact factor: 32.419

3.  Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.

Authors:  Thomas A Penfound; Edna Y Chiang; Elwaleed A Ahmed; James B Dale
Journal:  Vaccine       Date:  2010-05-21       Impact factor: 3.641

4.  Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.

Authors:  Ivette Caro-Aguilar; Elizabeth Ottinger; Robert W Hepler; Deborah D Nahas; Chengwei Wu; Michael F Good; Michael Batzloff; Joseph G Joyce; Jon H Heinrichs; Julie M Skinner
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

Review 5.  Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.

Authors:  Shu Ki Tsoi; Pierre R Smeesters; Hannah R C Frost; Paul Licciardi; Andrew C Steer
Journal:  J Immunol Res       Date:  2015-05-25       Impact factor: 4.818

Review 6.  Accelerating the development of a group A Streptococcus vaccine: an urgent public health need.

Authors:  Jean-Louis Excler; Jerome H Kim
Journal:  Clin Exp Vaccine Res       Date:  2016-07-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.